CTRI Announces Three New KL2 Grant Award Recipients

September 13, 2016

UC San Diego Clinical and Translational Research Institute (CTRI) recently selected three new KL2 awardees for 2016. As part of the CTRI Education program, KL2 awards provide a tailored mentored research experience to promising faculty clinical and translational researchers.

“We are delighted to announce the new KL2 award recipients, who were selected from an impressive group of applicants. The recipients are studying critical health questions on topics ranging from HIV prevention strategies, to treatment for a fatal brain infection in children, to evaluation of skeletal muscle loss in metastatic cancer patients,” said Colin Depp, PhD, Director of the Education program at CTRI.

The new KL2 scholars are from UC San Diego, with two from the Department of Medicine and one from the Skaggs School of Pharmacy and Pharmaceutical Sciences.

“One of our roles at CTRI is to encourage early career researchers to strengthen their abilities in clinical research as they learn from experienced faculty at UC San Diego,” said Joel Dimsdale, MD, Director of the CTRI KL2 Program. “The KL2 program, a Clinical and Translational Science Awards (CTSA) initiative to support junior faculty in translational research, provides an ideal vehicle for accomplishing this.” The CTSA program under the NIH National Center for Advancing Translational Sciences provides resources to train, cultivate and sustain future leaders of the biomedical research workforce.

The new awardees are:

Jill Blumenthal, MD
Department of Medicine, UC San Diego
Project Title: Barriers and Facilitators to PrEP Adherence in High-Risk HIV-uninfected Women in Southern California
Anjan Debnath, PhD
Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
Project Title: Targeting Cysteine Protease in Primary Amebic Meningoencephalitis

 

Eric Roeland, MD
Department of Medicine, UC San Diego
Project Title: FIT: Functional and Imaging Testing to Evaluate Body Composition and Functional Activity in Metastatic Cancer Patients

KL2 awardees receive up to three years of support from the CTRI and will be engaged in research and structured and experiential methodology-focused training, such as through our Clinical Research Enhancement through Supplemental Training (CREST) program. In addition, four researchers previously awarded will continue to receive KL2 support this year.

 

Click here to read more about the new KL2 awardees’ research, as well as a complete listing of the CTRI KL2 awardees.